When was 3DMed founded?

3DMed was founded in 2010 and raised its 1st funding round 7 years after it was founded.

Where is 3DMed located?

3DMed is headquartered in Shanghai, China.

Who is the current CEO of 3DMed?

Simon Shung and John Gong s of 3DMed. Simon Shung has also founded 1 company.

How many employees does 3DMed have?

As of Aug 31, 2026, the latest employee count at 3DMed is 108.

Is 3DMed a funded company?

3DMed is a funded company, having raised a total of $365M across 4 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Nov 23, 2017.

When was the latest funding round of 3DMed?

3DMed's latest funding was a $***** Series D round on Oct 19, 2020, with participation from 13 investors.

Where does 3DMed rank among its competitors?

3DMed ranks 72nd amongst 1016 active competitors, of which 218 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of 3DMed?

3DMed's top competitors include Guardant Health, Natera and Benchling. Among them, Guardant Health secured the most recent funding round in November, 2025.

3DMed - 2026 Company Profile, Team, Funding & Competitors

3DMed is a series D company based in Shanghai (China), founded in 2010 by Simon Shung. It operates as a Provider of personalized diagnostic treatment solutions for cancer. 3DMed has raised $365M in funding from investors like China Equity Group, Luxin Venture Capital Group and CPE. The company has 1016 active competitors, including 218 funded and 133 that have exited. Its top competitors include companies like Guardant Health, Natera and Benchling.

Company Details

Provider of personalized diagnostic treatment solutions for cancer. The company depends on an individual's genetic information for the production of precision medicine. The company sequences the genetic makeup of a patient to develop a personalized treatment. The company has different sets of gene profiles for detecting the mutation in genes that can lead to solid tumors or malignancy. The company has developed products for cancer detection, including histology genomic tests, ctDNA liquid biopsies, and exosome liquid biopsies.

Website: www.3dmedcare.com
Email ID: *****@3dmedcare.com, *****@3dmedcare.com
Phone Number: +86 **********

Key Metrics

Founded Year

2010

Location

Shanghai, China

Stage

Series D

Total Funding

$365M in 4 rounds

Latest Funding Round

Series D, Oct 19, 2020, $*****

Investors

China Equity Group & 24 more

Ranked

72^nd among 1016 active competitors

Employee Count

108 as on Aug 31, 2026

Similar Companies

Guardant Health & 1301 more

View 3DMed's full profile

3DMed has raised a total funding of $365M over 4 rounds. Its first funding round was on Nov 23, 2017. Its latest funding round was a Series D round on Oct 19, 2020 for $*****. 13 investors participated in its latest round. 3DMed has 24 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of 3DMed:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 19, 2020	4627718	Series D	7850066	8560048	8475187	5507970
Oct 09, 2020	1936151	Series C	6310838	1779585	2816511	ZHENG Zhigang & 2 more
Jan 06, 2020	9682461	Series C	2160453	3778956	Luxin Venture Capital Group	China Equity Group & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of 3DMed's funding rounds and investors

The founders of 3DMed is Simon Shung. Simon Shung and John Gong are the CEOs of 3DMed.

Here are the details of 3DMed's key team members:

Simon Shung: Founder, Chairman & Co-CEO of 3DMed and founder of 1 other company.
John Gong: CEO of 3DMed.

View details of 3DMed's Founder profiles and Board Members

3DMed's employee count trend

3DMed has 108 employees as of Aug 26. Here is 3DMed's employee count trend over the years:

Uncover 3DMed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 3DMed include Guardant Health, Natera and Benchling. Here is the list of Top 10 competitors of 3DMed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	77/100
3rd	Benchling 2012, San Francisco (United States), Series F	Provider of a cloud-based bioinformatics platform for biotech research	$412M	Altimeter Capital, Benchmark & 29 others	73/100
4th	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
5th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
6th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
7th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
8th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	68/100
9th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
72nd	3DMed 2010, Shanghai (China), Series D	Provider of personalized diagnostic treatment solutions for cancer	$365M	Spinnotec, Efung Capital & 23 others	46/100